Impact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease

Background/Aims: Few studies have analyzed the association between infliximab trough levels and clinical outcomes in patients with intestinal Behçet disease (BD). The authors investigated the role of infliximab trough levels as an independent predictive factor for clinical outcomes to infliximab in refractory intestinal BD. Materials and Methods: The authors analyzed 46 infliximab trough levels in 33 patients with intestinal BD between November 2019 and October 2025 at Severance Hospital, Seoul, South Korea. Clinical outcomes were compared between the high disease activity (n = 25) and normal or low disease activity (n = 21) groups. Results: In 46 intestinal BD cases with a mean disease duration of 9.8 Å} 8.6 years and a mean infliximab treatment duration of 27.6 months, the infliximab trough level in the high disease activity group was 3.3 μg/mL, whereas it was 7.6 μg/mL in the normal or low disease activity group (P = .039). A mean infliximab level > 7.55 μg/mL (area under the receiver operating characteristic [AUROC]: 0.614, 95% CI: 0.451-0.718, P = .186) was associated with normal or low disease activity, although it did not reach statistical significance. Based on the multivariate logistic regression analysis results, the infliximab trough level was positively associated with normal or low disease activity in intestinal BD (odds ratio [OR]: 1.146, 95% CI: 1.004-1.309, P = .004). C-reactive protein levels (OR: 0.946, 95% CI: 0.904-0.991, P = .019) and the presence of systemic BD manifestations (OR: 0.003, 95% CI: 0.000-0.840, P = .043) were negatively associated with normal or low disease activity. Conclusion: Higher infliximab trough levels were positively associated with normal or low disease activity to infliximab in intestinal BD. Cite this article as: Park J, Mun SY, Park SJ, Park JJ, Kim TI, Cheon JH. Impact of infliximab trough levels on clinical outcomes in patients with intestinal Behçet’s disease. Turk J Gastroenterol. Published online November 18, 2026. doi: 10.5152/tjg.2026.26709.

Authors

Institutions

Publication Details

Journal
The Turkish Journal of Gastroenterology
Published
2026-11-18
DOI
https://doi.org/10.5152/tjg.2026.26709
Primary Topic
Ocular Diseases and Behçet’s Syndrome
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Impact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease

Jae Hee Cheon, Tae Il Kim, Jihye Park, Jae Jun Park et al.
The Turkish Journal of Gastroenterology
Ocular Diseases and Behçet’s Syndrome
article

Impact of Infliximab Trough Levels on Clinical Outcomes in Patients with Intestinal Behçet’s Disease

Jae Hee Cheon, Tae Il Kim, Jihye Park, Jae Jun Park, Soo Jung Park, Seo Young Mun
article en

Abstract

Background/Aims: Few studies have analyzed the association between infliximab trough levels and clinical outcomes in patients with intestinal Behçet disease (BD). The authors investigated the role of infliximab trough levels as an independent predictive factor for clinical outcomes to infliximab in refractory intestinal BD. Materials and Methods: The authors analyzed 46 infliximab trough levels in 33 patients with intestinal BD between November 2019 and October 2025 at Severance Hospital, Seoul, South Korea. Clinical outcomes were compared between the high disease activity (n = 25) and normal or low disease activity (n = 21) groups. Results: In 46 intestinal BD cases with a mean disease duration of 9.8 Å} 8.6 years and a mean infliximab treatment duration of 27.6 months, the infliximab trough level in the high disease activity group was 3.3 μg/mL, whereas it was 7.6 μg/mL in the normal or low disease activity group (P = .039). A mean infliximab level > 7.55 μg/mL (area under the receiver operating characteristic [AUROC]: 0.614, 95% CI: 0.451-0.718, P = .186) was associated with normal or low disease activity, although it did not reach statistical significance. Based on the multivariate logistic regression analysis results, the infliximab trough level was positively associated with normal or low disease activity in intestinal BD (odds ratio [OR]: 1.146, 95% CI: 1.004-1.309, P = .004). C-reactive protein levels (OR: 0.946, 95% CI: 0.904-0.991, P = .019) and the presence of systemic BD manifestations (OR: 0.003, 95% CI: 0.000-0.840, P = .043) were negatively associated with normal or low disease activity. Conclusion: Higher infliximab trough levels were positively associated with normal or low disease activity to infliximab in intestinal BD. Cite this article as: Park J, Mun SY, Park SJ, Park JJ, Kim TI, Cheon JH. Impact of infliximab trough levels on clinical outcomes in patients with intestinal Behçet’s disease. Turk J Gastroenterol. Published online November 18, 2026. doi: 10.5152/tjg.2026.26709.

The Turkish Journal of Gastroenterology
Yonsei University (KR), Severance Hospital (KR), Gangnam Severance Hospital (KR), Yonsei University Health System (KR)
Good health and well-being
Ocular Diseases and Behçet’s Syndrome
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon